))
David Henry's JCSO podcast, February 2016
Manage episode 176141941 series 1414118
Content provided by David Henry’s JCSO Podcast and David Henry. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by David Henry’s JCSO Podcast and David Henry or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
For the February podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry examines two Original Reports, one on a collaborative investigation by scientists and members of a social network into fluoroquinolone-related neuropsychiatric and mitochondrial toxicity and another on the prognostic value of complete remission with superior platelet counts in patients with acute myeloid leukemia. The Case Reports this month focus on rare tumors: in one case, it is a metastatic primary bladder adenocarcinoma for which a novel treatment approach prolonged survival; and in a second, an 18-year follow-up on a rare, indolent form of T-cell prolymphocytic leukemia. The Community Translations column features the novel MEK inhibitor, cobimetinib, which was approved last year in combination with the BRAF inhibitor, vemurafenib, for metastatic melanoma with BRAF V600E or V600K mutation. Dr Henry also discusses articles on new therapies for gastrointestinal cancers and on selected practice-changing presentations from the 2015 annual meeting of the San Antonio Breast Cancer Symposium in Orlando last year.
…
continue reading
12 episodes
Share
